CN111012891A - 一种延缓动脉粥样硬化的中药组方及其制备方法 - Google Patents
一种延缓动脉粥样硬化的中药组方及其制备方法 Download PDFInfo
- Publication number
- CN111012891A CN111012891A CN201911362773.3A CN201911362773A CN111012891A CN 111012891 A CN111012891 A CN 111012891A CN 201911362773 A CN201911362773 A CN 201911362773A CN 111012891 A CN111012891 A CN 111012891A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- parts
- chinese medicine
- medicine formula
- atherosclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 241000132012 Atractylodes Species 0.000 claims abstract description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 5
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 5
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 5
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 5
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 5
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 5
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 5
- 235000008397 ginger Nutrition 0.000 claims abstract description 5
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 9
- 239000012535 impurity Substances 0.000 claims description 9
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 8
- 239000011362 coarse particle Substances 0.000 claims description 6
- 239000000428 dust Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 244000061520 Angelica archangelica Species 0.000 claims description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 4
- 235000008599 Poria cocos Nutrition 0.000 claims description 4
- 244000197580 Poria cocos Species 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 244000236658 Paeonia lactiflora Species 0.000 claims description 3
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 3
- 238000007667 floating Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000037326 chronic stress Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000014882 Carotid artery disease Diseases 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公布了延缓动脉粥样硬化的中药组方制备技术领域的一种延缓动脉粥样硬化的中药组方，由当归30份、白芍30份、柴胡30份、茯苓30份、白术30份、炙甘草15份、生姜15份和薄荷15份组成，首先选取所需重量份的药材进行浸泡，去除残渣后先后进行武火和文火煎煮制成，有助于理气化痰、活血通脉，有助于调节血脂水平、延缓动脉粥样硬化进程，能健脾化痰，起到祛瘀浊通血脉、延缓动脉粥硬化进程的作用，益于人体健康，能够从病根上祛病，起到养生保健的作用。
Description
技术领域
本发明涉及延缓动脉粥样硬化的中药组方制备技术领域，具体为一种延缓动脉粥样硬化的中药组方及其制备方法。
背景技术
随着社会经济快速发展，人们的工作节奏加快、生活方式以及饮食结构改变，动脉粥样硬化的发病率也呈逐年增长趋势，其造成的冠心病、脑卒中等心脑血管病是我国患者致残、致死的首要病因，因此延缓动脉粥样硬化无疑对心脑血管疾病的预防与预后起到关键的作用。临床上有如下与动脉粥样硬化病理进程密切相关的因素：（1）不良饮食、生活方式，造成高脂血症、肥胖、糖尿病等；（2）长期高强度工作、熬夜，造成内分泌系统紊乱；（3）高血压患者；（4）长期吸烟。从中医辩证论治上看，动脉粥样硬化的患者多属于气滞、血瘀、痰浊型，针对以上动脉粥样硬化的发病诱因及辩证特点，临床上多采用具有理气、化痰、活血中药组方进行治疗，中医药经典名方逍遥散正契合此治疗总则，其功效不但能疏肝理气、养肝活血，还能健脾化痰，逍遥散出自宋代《太平惠民和剂局方》，原方常用于情志病、妇科及肝胆等疾病，在动脉粥样硬化领域应用的报道则十分罕见，通过我们临床实践以及基础研究发现，逍遥散不仅能够调节内分泌水平，还能降低血脂、炎症指标水平，病理检查也显示能够改善动脉粥样硬化的病理进程。因此，通过对老方新用的研究，不仅拓展了逍遥散的适用范围，也为延缓动脉粥样硬化的治疗方案提供了新思路，因此，我们提出一种延缓动脉粥样硬化的中药组方及其制备方法。
发明内容
本发明的目的在于提供一种延缓动脉粥样硬化的中药组方及其制备方法，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：一种延缓动脉粥样硬化的中药组方，该种中药组方由以下重量份的原料药组成：
当归30份；
白芍30份；
柴胡30份；
茯苓30份；
白术30份；
炙甘草15份；
生姜15份；
薄荷15份。
一种延缓动脉粥样硬化的中药组方的制备方法具体步骤为：
A：将原料中药除去杂质和粉尘后，按照质量份比掺杂在一起，并且共粉碎成粗粒状，然后将其进行装包；
B：将步骤A中包好的原料中药先放入冷开水中浸泡50min，并保证冷开水量为装包药材重量份的10倍，然后将浸泡完成的水面上漂浮的杂物进行清除，再将浸泡好的药物和浸泡药物的澄清液一并放入砂锅内，注入过药65mm的冷开水进行第一次武火煎煮，煎煮时间为10min，然后转文火熬制30-60min煎煮至剩余7倍重量份的煎液，然后滤取药液，锅底剩余药渣；
C：然后向药渣中再次注入5倍于中药重量份的微温开水进行第二次武火煎煮，煎煮时间为10min，然后转文火熬制40-60min，再次滤取药液，并将残余的药渣倒掉；
D：将两次药液混合浓缩成中药液400ml即可。
优选的，步骤A中筛选杂志和粉尘时通过筛子进行筛选，然后在滤渣里进行药材挑拣，在筛子里将肉眼可见的杂质杂草进行剔除，并通过电子秤实现称重测量。
优选的，步骤B中浸泡完成的水面上的残渣通过滤勺进行清除，同时要保证砂锅中的水量不能低于中药重量份的7倍，且砂锅的内表壁上设置有刻度线。
与现有技术相比，本发明的有益效果是：
本发明中的中药组方有助于理气化痰、活血通脉，有助于调节血脂水平、延缓动脉粥样硬化进程，柴胡疏肝理气，薄荷有助柴胡疏肝郁而生之热，两者增强理气导滞之力，白芍养血柔肝，当归活血化瘀，两者合用使血充肝柔、血运通畅，白术、茯苓益脾气祛痰湿，煨生姜增强温胃和中之力，使运化有权、气血有源，炙甘草益气补中，缓肝之急，合方既可疏肝理气、养肝活血，还能健脾化痰，起到祛瘀浊通血脉、延缓动脉粥硬化进程的作用，益于人体健康，能够从病根上祛病，起到养生保健的作用。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例
一种延缓动脉粥样硬化的中药组方，该种中药组方由以下重量份的原料药组成：
当归30份；
白芍30份；
柴胡30份；
茯苓30份；
白术30份；
炙甘草15份；
生姜15份；
薄荷15份。
一种延缓动脉粥样硬化的中药组方的制备方法具体步骤为：
A：将原料中药除去杂质和粉尘后，按照质量份比掺杂在一起，并且共粉碎成粗粒状，然后将其进行装包；
B：将步骤A中包好的原料中药先放入冷开水中浸泡50min，并保证冷开水量为装包药材重量份的10倍，然后将浸泡完成的水面上漂浮的杂物进行清除，再将浸泡好的药物和浸泡药物的澄清液一并放入砂锅内，注入过药65mm的冷开水进行第一次武火煎煮，煎煮时间为10min，然后转文火熬制30-60min煎煮至剩余7倍重量份的煎液，然后滤取药液，锅底剩余药渣；
C：然后向药渣中再次注入5倍于中药重量份的微温开水进行第二次武火煎煮，煎煮时间为10min，然后转文火熬制40-60min，再次滤取药液，并将残余的药渣倒掉；
D：将两次药液混合浓缩成中药液400ml即可。
其中，步骤A中筛选杂志和粉尘时通过筛子进行筛选，然后在滤渣里进行药材挑拣，在筛子里将肉眼可见的杂质杂草进行剔除，并通过电子秤实现称重测量；
步骤B中浸泡完成的水面上的残渣通过滤勺进行清除，同时要保证砂锅中的水量不能低于中药重量份的7倍，且砂锅的内表壁上设置有刻度线。
一、临床试验
1.一般资料：气滞血瘀型颈动脉粥样硬化患者60例，男性29例，女性31例，其中年龄最大74岁，年龄最小37岁。
2.治疗方法：随机分为对照组和观察组，对照组采用常规西医基础治疗，观察组在对照组基础治疗上给予实施例1煎煮的中药组方，每剂用2日，每日两次餐后服用，4周为一个疗程，一共6个疗程。
3.疗效指标：（1）颈动脉彩超斑块检测（内膜中膜厚度、Crouse积分）；（2）血脂水平（低密度脂蛋白、高密度脂蛋白、甘油三酯、总胆固醇）。
4.结果：（1）治疗后观察组患者颈动脉彩超检测内膜中厚度、Crouse积分显著低于与对照组；（2）治疗后观察组患者低密度脂蛋白、甘油三酯、总胆固醇水平显著低于对照组。
5.安全性：在临床应用过程中我们始终注意本汤剂安全性观察，患者均未出现心肝肾功能等不良反应，长时间使用说明本片剂临床应用安全可靠，该种中药组方适用于气滞血瘀型颈动脉粥样硬化患者，此类患者平素饮食不节、高强度工作压力、昼夜颠倒，造成机体气滞血瘀，此中药组方有助于理气化痰、活血通脉，有助于调节血脂水平、延缓动脉粥样硬化进程。
二、基础实验
1.一般资料：ApoE-/-小鼠40只，雄性、6-8周龄、体重18-26g。
2.干预措施：随机分为4组，每组10只，第一组为慢性应激模型组，第二、第三、第四组在慢性应激造模的基础上分别实施例1制备的中药汤剂浓缩后以1份、2份、4份进行灌胃，连续给药60天。
3.观察指标：（1）血脂水平（低密度脂蛋白、高密度脂蛋白、甘油三酯、总胆固醇）；（2）炎症指标（IFN-γ,IL-6,IL-1β,TNFα）；（3）主动脉粥样硬化病理切片。
4.结果：（1）经干预后，中药组方各组血脂水平（低密度脂蛋白、甘油三酯、总胆固醇）显著低于慢性应激模型组，降低幅度与中药浓度呈正相关；（2）经干预后，中药组方各组炎症指标（IFN-γ,IL-6,IL-1β,TNFα）显著低于慢性应激模型组，降低幅度与中药浓度呈正相关；（3）经干预后，中药组方各组病理切片显示的动脉粥样硬化程度较慢性应激模型组有显著改善，改善程度与中药浓度呈正相关。
三、长期毒性试验
选取SD大鼠80只，随机分成四组，每组20只，第一组为对照组，常规喂养，第二、第三、第四组分别在常规饲养条件下将实施例1制备的中药汤剂浓缩后以1份、2份、4进行灌胃，连续灌胃给药8周，观察本发明的中药组合物对动物各项指标的影响。
试验结果表明，连续给药8周，本发明的中药组合物对大鼠的体重、摄食量、外周血象、脏器指数等均无明显影响；各指标与对照组比较无明显差异。在常规饲养两周后恢复期各给药组各项指标测定值与对照组比较均无明显差异，各组各脏器大体观察未见异常。
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物限定。
Claims (4)
1.一种延缓动脉粥样硬化的中药组方，其特征在于：该种中药组方由以下重量份的原料药组成：
当归30份；
白芍30份；
柴胡30份；
茯苓30份；
白术30份；
炙甘草15份；
生姜15份；
薄荷15份。
2.根据权利要求1所述的一种延缓动脉粥样硬化的中药组方，其特征在于：该种中药组方的制备方法具体步骤为：
A：将原料中药除去杂质和粉尘后，按照质量份比掺杂在一起，并且共粉碎成粗粒状，然后将其进行装包；
B：将步骤A中包好的原料中药先放入冷开水中浸泡50min，并保证冷开水量为装包药材重量份的10倍，然后将浸泡完成的水面上漂浮的杂物进行清除，再将浸泡好的药物和浸泡药物的澄清液一并放入砂锅内，注入过药65mm的冷开水进行第一次武火煎煮，煎煮时间为10min，然后转文火熬制30-60min煎煮至剩余7倍重量份的煎液，然后滤取药液，锅底剩余药渣；
C：然后向药渣中再次注入5倍于中药重量份的微温开水进行第二次武火煎煮，煎煮时间为10min，然后转文火熬制40-60min，再次滤取药液，并将残余的药渣倒掉；
D：将两次药液混合浓缩成中药液400ml即可。
3.根据权利要求2所述的一种延缓动脉粥样硬化的中药组方，其特征在于：步骤A中筛选杂志和粉尘时通过筛子进行筛选，然后在滤渣里进行药材挑拣，在筛子里将肉眼可见的杂质杂草进行剔除，并通过电子秤实现称重测量。
4.根据权利要求2所述的一种延缓动脉粥样硬化的中药组方，其特征在于：步骤B中浸泡完成的水面上的残渣通过滤勺进行清除，同时要保证砂锅中的水量不能低于中药重量份的7倍，且砂锅的内表壁上设置有刻度线。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911362773.3A CN111012891A (zh) | 2019-12-26 | 2019-12-26 | 一种延缓动脉粥样硬化的中药组方及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911362773.3A CN111012891A (zh) | 2019-12-26 | 2019-12-26 | 一种延缓动脉粥样硬化的中药组方及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111012891A true CN111012891A (zh) | 2020-04-17 |
Family
ID=70213663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911362773.3A Pending CN111012891A (zh) | 2019-12-26 | 2019-12-26 | 一种延缓动脉粥样硬化的中药组方及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111012891A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623599A (zh) * | 2004-03-26 | 2005-06-08 | 中奇制药技术（石家庄）有限公司 | 逍遥软胶囊及其制备工艺 |
| CN102100894A (zh) * | 2009-12-17 | 2011-06-22 | 苏州知微堂生物科技有限公司 | 一种逍遥散整合型新剂型制备技术及其生产方法 |
| CN104189833A (zh) * | 2014-09-11 | 2014-12-10 | 江西九华药业有限公司 | 一种逍遥丸的制备工艺 |
| CN106177856A (zh) * | 2016-08-18 | 2016-12-07 | 上海典实医疗科技有限公司 | 逍遥丸及其制备方法 |
| CN106310202A (zh) * | 2016-10-18 | 2017-01-11 | 上海辰松新材料科技有限公司 | 逍遥丸 |
-
2019
- 2019-12-26 CN CN201911362773.3A patent/CN111012891A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623599A (zh) * | 2004-03-26 | 2005-06-08 | 中奇制药技术（石家庄）有限公司 | 逍遥软胶囊及其制备工艺 |
| CN102100894A (zh) * | 2009-12-17 | 2011-06-22 | 苏州知微堂生物科技有限公司 | 一种逍遥散整合型新剂型制备技术及其生产方法 |
| CN104189833A (zh) * | 2014-09-11 | 2014-12-10 | 江西九华药业有限公司 | 一种逍遥丸的制备工艺 |
| CN106177856A (zh) * | 2016-08-18 | 2016-12-07 | 上海典实医疗科技有限公司 | 逍遥丸及其制备方法 |
| CN106310202A (zh) * | 2016-10-18 | 2017-01-11 | 上海辰松新材料科技有限公司 | 逍遥丸 |
Non-Patent Citations (1)
| Title |
|---|
| 杨大男等: "逍遥丸治疗高脂血症84例", 《陕西中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103789177B (zh) | 一种益气养阴复方太子参保健酒 | |
| CN103330121A (zh) | 一种用于血虚体质调理的功能性食品及其制备方法 | |
| CN104644915A (zh) | 一种治疗酒精性肝病的药物组合物及其制备方法和用途 | |
| CN1558768A (zh) | 一种中药组合物及其制备方法 | |
| CN109985209A (zh) | 一种治疗中晚期胃癌的中药组合物及其制备方法和应用 | |
| CN108310298A (zh) | 一种具有缓解眼疲劳、防治近视的中药组合物及制备方法 | |
| CN104815316A (zh) | 一种治疗急慢性胰腺炎的中药制剂及其制备方法 | |
| CN105311383B (zh) | 一种预防和改善视疲劳的保健中药组合物及其制备方法 | |
| CN105919111A (zh) | 一种水果酵素及其制备方法 | |
| CN111012891A (zh) | 一种延缓动脉粥样硬化的中药组方及其制备方法 | |
| CN1099835C (zh) | 降脂饮液或茶 | |
| CN104606337A (zh) | 一种用于治疗胆汁淤积性黄疸的中药 | |
| CN104826049B (zh) | 一种防治动脉粥样硬化的药膳及其制备方法和用途 | |
| CN105456652A (zh) | 一种治疗血脂异常和冠心病的中药制剂及其制备方法 | |
| CN112294917A (zh) | 一种治疗湿热蕴结证痛风的复方制剂及其制备方法 | |
| CN102106992B (zh) | 一种治疗非酒精性脂肪性肝炎的中药颗粒 | |
| CN101683386B (zh) | 一种具有降低血压作用中药酒的配方与制备方法 | |
| CN104800662A (zh) | 一种治疗老年心力衰竭的中药及制备方法 | |
| CN105816549B (zh) | 一种防治动脉粥样硬化斑块的药物及其制备方法 | |
| CN100384458C (zh) | 肝康药物组合物及其生产方法 | |
| CN104257960A (zh) | 一种治疗非酒精性脂肪肝的中药组合物及其应用 | |
| CN102973817A (zh) | 一种治疗动脉粥样硬化的中药复方制剂及其制备方法 | |
| CN108478706A (zh) | 一种保护心血管的组合物及其制备方法 | |
| LU504091B1 (en) | Traditional chinese medicine preparation for enhancing antiviral efficacy of entecavir combined with chb and nafld, preparation method thereof and combined therapeutic drug | |
| CN103316106A (zh) | 丹山消脂颗粒及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200417 |